STM2457 靶向 METTL3 的抗肿瘤作用机制及临床应用进展

吕欣慧 ,  王佳琳 ,  王喆 ,  梁珊珊 ,  王若雨

大连医科大学学报 ›› 2026, Vol. 48 ›› Issue (3) : 245 -251.

PDF (1122KB)
大连医科大学学报 ›› 2026, Vol. 48 ›› Issue (3) : 245 -251. DOI: 10.11724/jdmu.2026.03.08
综述

STM2457 靶向 METTL3 的抗肿瘤作用机制及临床应用进展

作者信息 +

METTL3 inhibitor STM2457: antitumor mechanisms and clinical application progress

Author information +
文章历史 +
PDF (1148K)

摘要

N6-甲基腺苷(m6A)甲基化修饰作为 RNA 层面的关键表观遗传调控方式,在肿瘤的发生、进展、侵袭及免疫逃逸过程中具有重要作用。甲基转移酶样蛋白 3(METTL3)是 m6A 甲基转移复合物的核心催化亚基,其异常激活被认为是多种恶性肿瘤发生的驱动因素。近年来,随着高选择性小分子抑制剂 STM2457 及临床候选药物 STC-15 的研发,靶向 METTL3 的抗肿瘤研究实现了从基础机制探索到临床转化的突破。本综述系统总结了 STM2457 的药物结构、作用机制、联合治疗策略及临床试验研究进展。

Abstract

N6-methyladenosine (m6A) methylation modification is a crucial epigenetic regulatory mechanism at the RNA level, playing an important role in tumorigenesis, progression, and immune evasion. Methyltransferase-like protein 3 (METTL3) is the core catalytic subunit of the m6A methyltransferase complex, and its aberrant activation is considered a driving factor in the development of various malignant tumors. In recent years, with the development of highly selective inhibitors such as STM2457 and the clinical candidate drug STC-15, antitumor research targeting METTL3 has achieved breakthrough from basic mechanism exploration to clinical translation. This review comprehensively elaborates on the molecular structure, functional mechanism, combination therapy regimens, and clinical trial progress of the METTL3 inhibitor STM2457.

关键词

STM2457 / METTL3 / N6-甲基腺苷修饰 / 表观遗传 / 靶向治疗

Key words

STM2457 / METTL3 / N6-methyladenosine / epigenetics / targeted therapy

引用本文

引用格式 ▾
吕欣慧,王佳琳,王喆,梁珊珊,王若雨. STM2457 靶向 METTL3 的抗肿瘤作用机制及临床应用进展[J]. 大连医科大学学报, 2026, 48(3): 245-251 DOI:10.11724/jdmu.2026.03.08

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Shen CQ, Xuan BQ, Yan TT, et al. m6A-dependent glycolysis enhances colorectal cancer progression[J]. Mol Cancer, 2020, 19(1): 72. DOI: 10.1186/s12943-020-01190-w.

[2]

Gray KA, Yates B, Seal RL, et al. Genenames. org: the HGNC resources in 2015[J]. Nucleic Acids Res, 2015, 43(D1): D1079-D1085. DOI: 10.1093/nar/gku1071.

[3]

Sun YC, Gong WP, Zhang S. METTL3 promotes colorectal cancer progression through activating JAK1/STAT3 signaling pathway[J]. Cell Death Dis, 2023, 14: 765. DOI: 10.1038/s41419-023-06287-w.

[4]

Vu LP, Pickering BF, Cheng YM, et al. The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells[J]. Nat Med, 2017, 23(11): 1369-1376. DOI: 10.1038/nm.4416.

[5]

Xiao H, Zhao R, Meng WY, et al. Effects and translatomics characteristics of a small-molecule inhibitor of METTL3 against non-small cell lung cancer[J]. J Pharm Anal, 2023, 13(6): 625-639. DOI: 10.1016/j.jpha.2023.04.009.

[6]

Zhao Y, Zhang L, Xia L, et al. A METTL3-NFE2L3 axis mediates tumor stemness and progression in lung adenocarcinoma[J]. Sci Adv, 2025, 11(16): eadt7682. DOI: 10.1126/sciadv.adt7682.

[7]

Barbieri I, Tzelepis K, Pandolfini L, et al. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control[J]. Nature, 2017, 552(7683): 126-131. DOI: 10.1038/nature24678.

[8]

Dolbois A, Bedi RK, Bochenkova E, et al. 1, 4, 9-triazaspiro[5.5] undecan-2-one derivatives as potent and selective METTL3 inhibitors[J]. J Med Chem, 2021, 64(17): 12738-12760.

[9]

Li Y, Xia LJ, Tan KF, et al. N6-Methyladenosine co-transcriptionally directs the demethylation of histone H3K9me2[J]. Nat Genet, 2020, 52(9): 870-877. DOI: 10.1038/s41588-020-0677-3.

[10]

Chen MN, Wei L, Law CT, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2 [J]. Hepatology, 2018, 67(6): 2254-2270. DOI: 10.1002/hep.29683.

[11]

Lin SB, Choe J, Du P, et al. The m6A methyltransferase METTL3 promotes translation in human cancer cells[J]. Mol Cell, 2016, 62(3): 335-345. DOI: 10.1016/j.molcel.2016.03.021.

[12]

Wang W, Shao F, Yang XY, et al. METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding[J]. Nat Commun, 2021, 12: 3803. DOI: 10.1038/s41467-021-23501-5.

[13]

王安祺. METTL3 调控 SRPK1 的 m6A 甲基化修饰介导有氧糖酵解促进肺腺癌细胞增殖的机制研究[D]. 苏州: 苏州大学, 2023.

[14]

Chen X, Wang MM, Wang HR, et al. METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3/AKT pathway and synergizes with PARP inhibitor [J]. Biomed Pharmacother, 2024, 179: 117366. DOI: 10.1016/j.biopha.2024.117366.

[15]

Yu Y, Hai YN, Zhou HF, et al. METTL3 inhibition suppresses cell growth and survival in colorectal cancer via ASNS downregulation [J]. J Cancer, 2024, 15(15): 4853-4865. DOI: 10.7150/jca.96760.

[16]

庄家敏, 赵培培, 杨媛媛, 等. STM2457 经 YTHDF1/EIF3C 抑制 Huh-7 肝癌细胞增殖[J]. 华夏医学, 2025, 38(1): 22-27. DOI: 10.19296/j.cnki.1008-2409.2025-01-004.

[17]

Yi Y, Fry J, Yum C, et al. EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of m6A autoregulation pathway[J]. J Clin Investig, 2026, 136(2): e195840. DOI: 10.1172/jci195840.

[18]

高川力, 周锡, 邹江, 等. 甲基化转移酶 3 对食管癌细胞增殖、迁移及谷氨酰胺代谢的影响[J]. 中国生物制品学杂志, 2024, 37(5): 544-553, 558. DOI: 10.13200/j.cnki.cjb.004223.

[19]

Jiao CQ, Hu C, Sun MH, et al. Targeting METTL3 mitigates venetoclax resistance via proteasome-mediated modulation of MCL1 in acute myeloid leukemia [J]. Cell Death Dis, 2025, 16: 233. DOI: 10.1038/s41419-025-07560-w.

[20]

Wu X, Ye W, Gong YP. The role of RNA methyltransferase METTL3 in normal and malignant hematopoiesis[J]. Front Oncol, 2022, 12: 873903. DOI: 10.3389/fonc.2022.873903.

[21]

Yankova E, Blackaby W, Albertella M, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia[J]. Nature, 2021, 593(7860): 597-601. DOI: 10.1038/s41586-021-03536-w.

[22]

Shan GS, Wang WR, Li XQ, et al. Epigenetic-targeted biomimetic nanomedicine modulates epithelial mesenchymal transition to enhance chemosensitivity in heterogeneous tumors[J]. Biomaterials, 2026, 324: 123529. DOI: 10.1016/j.biomaterials.2025.123529.

[23]

刘博琛. ZBTB7A m6A 修饰在结直肠癌肝转移中作用及机制研究[D]. 济南: 山东大学, 2024.

[24]

Meng HN, Jalal M, Wang H, et al. 17-AAG promotes the degradation of HSP90 client METTL3 to suppress MYC RNA m6A modification and expression in colorectal cancer[J]. Int J Biol Macromol, 2026, 337: 149421. DOI: 10.1016/j.ijbiomac.2025.149421.

[25]

Hao SL, Sun HT, Sun H, et al. STM2457 inhibits the invasion and metastasis of pancreatic cancer by down-regulating BRAF-activated noncoding RNA N6-methyladenosine modification[J]. Curr Issues Mol Biol, 2023, 45(11): 8852-8863. DOI: 10.3390/cimb45110555.

[26]

吴荣寿. METTL3 介导 RNA 甲基化修饰调控 PD-L1 表达促进肝癌免疫逃逸的机制研究[D]. 南昌: 南昌大学, 2024.

[27]

Wu KX, Li S, Hong GL, et al. Targeting METTL3 as a checkpoint to enhance T cells for tumour immunotherapy[J]. Clin Transl Med, 2024, 14(11): e70089. DOI: 10.1002/ctm2.70089.

[28]

李敏. Mettl3/Ythdf2 介导的 Egr1m6A 修饰在调控结直肠癌单核样髓源性抑制细胞分化中的作用机制研究[D]. 镇江: 江苏大学, 2024.

[29]

Tong YH, Chen ZQ, Wu J, et al. METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5/CCL5 regulation [J]. J Immunother Cancer, 2025, 13(4): e011108. DOI: 10.1136/jitc-2024-011108.

[30]

Gao CL, Yang H, Cheng J, et al. STM2457 impairs the proliferation of esophageal squamous cell carcinoma by activating DNA damage response through ATM-Chk2 axis[J]. Med Oncol, 2025, 42(3): 82. DOI: 10.1007/s12032-025-02634-3.

[31]

Jin XH, Lv YR, Bie FJ, et al. METTL3 confers oxaliplatin resistance through the activation of G6PD-enhanced pentose phosphate pathway in hepatocellular carcinoma[J]. Cell Death Differ, 2025, 32(3): 466-479. DOI: 10.1038/s41418-024-01406-2.

[32]

Xuan YF, Lu S, Ou YJ, et al. The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity[J]. Biochem Biophys Res Commun, 2024, 716: 150011. DOI: 10.1016/j.bbrc.2024.150011.

[33]

Zhang R, Chen P, Wang YB, et al. Targeting METTL3 enhances the chemosensitivity of non-small cell lung cancer cells by decreasing ABCC2 expression in an m6A-YTHDF1-dependent manner[J]. Int J Biol Sci, 2024, 20(12): 4750-4766. DOI: 10.7150/ijbs.97425.

[34]

柏睿. APC 突变通过 METTL3-VISTA 信号轴介导结直肠癌免疫逃逸的机制研究[D]. 广州: 南方医科大学, 2024.

[35]

赵荣. 靶向 METTL3 在 NSCLC 中增强免疫抑制剂抗肿瘤效应的机制研究[D]. 武汉: 华中科技大学, 2024.

[36]

Li ZS, Zhang XY, Liu C, et al. Engineering a nano-drug delivery system to regulate m6A modification and enhance immunotherapy in gastric cancer[J]. Acta Biomater, 2025, 191: 412-427. DOI: 10.1016/j.actbio.2024.11.036.

[37]

Pan YS, Chen HR, Zhang X, et al. METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy[J]. Cell Rep Med, 2023, 4(8): 101144. DOI: 10.1016/j.xcrm.2023.101144.

[38]

Eleftheriou M, Russell J, Tzelepis K. Epitranscriptomic advances in normal and malignant hematopoiesis[J]. Leukemia, 2025, 39(12): 2848-2857. DOI: 10.1038/s41375-025-02765-6.

[39]

Ofir-Rosenfeld Y, Vasiliauskaitė L, Saunders C, et al. 345 (PB125) STC-15, an oral small molecule inhibitor of the RNA methyltransferase METTL3, inhibits tumour growth through activation of anti-cancer immune responses associated with increased interferon signalling, and synergises with T cell checkpoint blockade[J]. Eur J Cancer, 2022, 174: S123. DOI: 10.1016/S0959-8049(22)01128-5.

[40]

Tang HR, Zhang RJ. Small-molecule inhibitors targeting RNA m6A modifiers for cancer therapeutics: latest advances and future perspectives[J]. J Med Chem, 2025, 68(17): 18114-18142. DOI: 10.1021/acs.jmedchem.5c01570.

[41]

Wu ZX, Smith AR, Qian ZJ, et al. Patent landscape of small molecule inhibitors of METTL3 (2020-present)[J]. Expert Opin Ther Pat, 2025, 35(3): 305-320. DOI: 10.1080/13543776.2024.2447056.

[42]

Nejatie A, Yee SS, Jeter A, et al. The cancer glycocode as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides[J]. Front Oncol, 2023, 13: 1261090. DOI: 10.3389/fonc.2023.1261090.

[43]

Bedi RK, Huang DZ, Eberle SA, et al. Small-molecule inhibitors of METTL3, the major human epitranscriptomic writer[J]. ChemMedChem, 2020, 15(9): 744-748. DOI: 10.1002/cmdc.202000011.

[44]

Brewer G. METTL3 inhibition enhances anti-tumour immunity[J]. Nat Rev Cancer, 2023, 23(10): 654. DOI: 10.1038/s41568-023-00621-2.

[45]

Moroz-Omori EV, Huang DZ, Kumar Bedi R, et al. METTL3 inhibitors for epitranscriptomic modulation of cellular processes[J]. ChemMedChem, 2021, 16(19): 3035-3043. DOI: 10.1002/cmdc.202100291.

[46]

Lee JH, Kim S, Jin MS, et al. Discovery of substituted indole derivatives as allosteric inhibitors of m6A-RNA methyltransferase, METTL3-14 complex[J]. Drug Dev Res, 2022, 83(3): 783-799. DOI: 10.1002/ddr.21910.

[47]

Xia Y, Wang YD, Chen K, et al. Quercetin attenuated necroptosis and apoptosis caused by LPS-induced mitochondrial function dysfunction through the METTL3-mediated PTEN m6A methylation/PI3K/AKT signaling in broiler livers[J]. Phytomedicine, 2025, 139: 156551. DOI: 10.1016/j.phymed.2025.156551.

[48]

Du Y, Yuan YL, Xu L, et al. Discovery of METTL3 small molecule inhibitors by virtual screening of natural products[J]. Front Pharmacol, 2022, 13: 878135. DOI: 10.3389/fphar.2022.878135.

[49]

Fu W, Liu LX, Tong SJ. Berberine inhibits the progression of breast cancer by regulating METTL3-mediated m6A modification of FGF7 mRNA[J]. Thorac Cancer, 2024, 15(17): 1357-1368. DOI: 10.1111/1759-7714.15321.

[50]

Cheng SY, Chen LQ, Ying JH, et al. 20(S)-ginsenoside Rh2 ameliorates ATRA resistance in APL by modulating lactylation-driven METTL3[J]. J Ginseng Res, 2024, 48(3): 298-309. DOI: 10.1016/j.jgr.2023.12.003.

基金资助

国家自然科学基金项目(82172822)

辽宁省国际科技合作项目(2024JH2/101900006)

辽宁省科学技术计划-联合计划-关键技术攻关项目(2024JH2/102600067)

大连大学交叉学科发展项目(DLUXK-2025-FX-001)

AI Summary AI Mindmap
PDF (1122KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉